IPA	isopropanol
LCMS	liquid chromatography mass spectrometry
LiHMDS	lithium bis(trimethylsilyl)amide
MeOH	methanol
min	minute(s)
MS	mass spectrometry
MW	microwave(s)
NH_4OAc	ammonium acetate
NMR	nuclear magnetic resonance
ox	oxidation
Psi	pounds per square inch
quant.	quantitative
RCM	ring closing metathesis
r.t.	room temperature
sat.	saturated
SFC	supercritical fluid chromatography
TFA	trifluoroacetic acid
THF	tetrahydrofuran
TLC	thin layer chromatography
TMEDA	tetramethylethylenediamine
UPLC	ultra performance liquid chromatography
2-Me THF	2-methyl tetrahydrofuran

Compounds have been named using CambridgeSoft MedChem ELN v2.2 or ACD/Name, version 10.0, or 10.06, or version 12.01, software from Advanced Chemistry Development, Inc. (ACD/Labs), Toronto ON, Canada, www.acdlabs.com, or Lexichem, version 1.9, software from OpenEye.

EXAMPLES

~~Below follows a number of non-limiting examples of compounds of the invention.~~

Intermediate 1

CLAIMS

1. A compound according to formula (I):



(I)

wherein

A is -O- or -CH_2-;

n is 0 or 1;

R^1 is C_{1-6}alkyl or C_{1-6}haloalkyl;

R^2 is hydrogen, C_{0-6}alkylaryl, C_{0-6}alkylheteroaryl, C_{2-6}alkynyl, C_{2-6}alkenyl, C_{1-6}alkyl, halogen, cyano, C_{1-6}haloalkyl, NHC(O)R^9 or OR^8, wherein said C_{0-6}alkylaryl, C_{0-6}alkyl-heteroaryl, C_{2-6}alkynyl, C_{2-6}alkenyl, C_{1-6}alkyl or C_{1-6}haloalkyl is optionally substituted with one to three R^7;

R^5 and R^6 are independently hydrogen, heterocyclyl, C_{3-6}cycloalkyl, aryl, heteroaryl or C_{1-6}alkyl, wherein said heterocyclyl, C_{3-6}cycloalkyl, aryl, heteroaryl or C_{1-6}alkyl is optionally substituted with one or two substituents independently selected from halogen, C_{1-6}alkyl, C_{1-6}haloalkyl, cyano or OR^8;
or R^5 and R^6 together with the carbon to which they are attached, form a ring B, which is a 3-14 membered cycloalkyl or heterocyclyl monocyclic ring, or a 9-14 membered bicyclic cycloalkyl or heterocyclyl ring; and wherein ring B is optionally substituted by one or two substituents independently selected from oxo, halogen, C_{1-6}alkyl, C_{1-6}haloalkyl, cyano, or OR^8; and ring B is optionally fused with an aryl or heteroaryl to form a bi- or polycyclic system;

R^7 is independently C_{1-6}alkyl, halogen, cyano, C_{0-6}alkylC_{3-6}cycloalkyl, C_{1-6}haloalkyl, OC_{1-6}alkyl, OC_{1-6}haloalkyl, C_{2-6}alkynyl or C_{2-6}alkenyl, wherein said C_{1-6}alkyl, C_{0-6}alkylC_{3-6}cycloalkyl, C_{1-6}haloalkyl, OC_{1-6}alkyl, OC_{1-6}haloalkyl, C_{2-6}alkynyl or C_{2-6}alkenyl is optionally substituted with 1-3 substituents independently selected from halogen, cyano, C_{1-6}alkyl, C_{1-6}haloalkyl, OC_{1-6}alkyl and OC_{1-6}haloalkyl;

R^8 is independently hydrogen, C_{1-6}alkyl, C_{2-6}alkynyl, C_{1-6}haloalkyl, aryl or heteroaryl, wherein said C_{1-6}alkyl, C_{1-6}haloalkyl, aryl or heteroaryl is optionally substituted with a group selected from halogen, cyano and C_{1-6}alkyl;

R^9 is a heteroaryl, wherein said heteroaryl is optionally substituted with halogen, cyano, OR^8, C_{1-6}haloalkyl or C_{1-6}alkyl;

as a free base or a pharmaceutically acceptable salt thereof.

2. A compound according to claim 1, or a pharmaceutically acceptable salt thereof, wherein R^1 is C_{1-3}alkyl.

3. A compound according to claim 2, or a pharmaceutically acceptable salt thereof, wherein R^1 is methyl or ethyl.

4. A compound according to any one of claims 1-3, or a pharmaceutically acceptable salt thereof, wherein R^2 is aryl, heteroaryl, C_{2-6}alkynyl, halogen, $NHC(O)R^9$ or OR^8, wherein said aryl, heteroaryl, or C_{2-6}alkynyl is optionally substituted with one to three R^7.

5. A compound according to any one of claims 1-4, or a pharmaceutically acceptable salt thereof, wherein R^5 and R^6 are independently hydrogen or heterocyclyl wherein said heterocyclyl is optionally substituted with one or two substituents independently selected from C_{1-6}alkyl or OR^8.

6. A compound according to any one of claims 1-4, or a pharmaceutically acceptable salt thereof, wherein R^5 and R^6 together with the carbon to which they are attached, form a ring B, which is a 3-14 membered cycloalkyl or heterocyclyl monocyclic ring, or a 9-14

membered bicyclic cycloalkyl or heterocyclyl ring; and wherein ring B is optionally substituted by one or two substituents independently selected from oxo, halogen, C_{1-6}alkyl or OR^8; and ring B is optionally fused with an aryl or heteroaryl to form a bi- or polycyclic system.

7. A compound according to any one of claims 1-4 or 6, or a pharmaceutically acceptable salt thereof, wherein R^5 and R^6 together with the carbon to which they are attached form a cyclohexyl ring, which is substituted with OR^8.

8. A compound according to any one of claims 1-7, or a pharmaceutically acceptable salt thereof, wherein R^7 is independently C_{1-6}alkyl, halogen, cyano, C_{0-6}alkylC_{3-6}cycloalkyl, C_{1-6}haloalkyl, OC_{1-6}alkyl or C_{2-6}alkynyl, wherein said C_{1-6}alkyl, C_{0-6}alkylC_{3-6}cycloalkyl, C_{1-6}haloalkyl, OC_{1-6}alkyl or C_{2-6}alkynyl is optionally substituted with 1-3 substituents independently selected from halogen, cyano, C_{1-6}alkyl, C_{1-6}haloalkyl, OC_{1-6}alkyl and OC_{1-6}haloalkyl.

9. A compound according to any one of claims 1-8, or a pharmaceutically acceptable salt thereof, wherein R^8 is independently C_{1-6}alkyl, C_{2-6}alkynyl or C_{1-6}haloalkyl.

10. A compound according to any one of claims 1-9, or a pharmaceutically acceptable salt thereof, wherein R^9 is heteroaryl, wherein said heteroaryl is optionally substituted with halogen, cyano, OR^8, C_{1-6}haloalkyl or C_{1-6}alkyl.

11. A compound according to claim 1, or a pharmaceutically acceptable salt thereof, wherein

A is -O- or -CH_2 -;
n is 0 or 1;

R^1 is C_{1-6}alkyl;

R^2 is C_{0-6}alkylaryl, C_{0-6}alkylheteroaryl, C_{2-6}alkynyl, halogen, NHC(O)R^9 or OR^8; wherein said C_{0-6}alkylaryl, C_{0-6}alkylheteroaryl or C_{2-6}alkynyl is optionally substituted with one to three R^7;

R^5 and R^6 are independently hydrogen or heterocyclyl, wherein said heterocyclyl is optionally substituted with one or two substituents independently selected from halogen, C_{1-6}alkyl, C_{1-6}haloalkyl, cyano or OR^8;

or R^5 and R^6 together with the carbon to which they are attached, form a ring B, which is a 3-14 membered cycloalkyl or heterocyclyl monocyclic ring, or a 9-14 membered bicyclic cycloalkyl or heterocyclyl ring; and wherein ring B is optionally substituted by one or two substituents independently selected from oxo, halogen, C_{1-6}alkyl or OR^8; and ring B is optionally fused with an aryl or heteroaryl to form a bi- or polycyclic system;

R^7 is independently C_{1-6}alkyl, halogen, cyano, C_{0-6}alkylC_{3-6}cycloalkyl, C_{1-6}haloalkyl, OC_{1-6}alkyl or C_{2-6}alkynyl, wherein said C_{1-6}alkyl, C_{0-6}alkylC_{3-6}cycloalkyl, C_{1-6}haloalkyl, OC_{1-6}alkyl or C_{2-6}alkynyl, is optionally substituted with 1-3 substituents independently selected from halogen, cyano, C_{1-6}alkyl, C_{1-6}haloalkyl, OC_{1-6}alkyl and OC_{1-6}haloalkyl;

R^8 is independently C_{1-6}alkyl, C_{2-6}alkynyl or C_{1-6}haloalkyl, wherein said C_{1-6}alkyl, C_{1-6}haloalkyl, aryl or heteroaryl is optionally substituted with a group selected from halogen, cyano or C_{1-6}alkyl; and

R^9 is heteroaryl, wherein said heteroaryl is optionally substituted with halogen, cyano, OR^8, C_{1-6}haloalkyl or C_{1-6}alkyl;

12. A compound according to claim 1, or a pharmaceutically acceptable salt thereof, wherein

A is -O- or -CH_2 -;
n is 0 or 1;

R^1 is C_{1-3}alkyl;

R^2 is aryl, heteroaryl, C_{2-6}alkynyl, halogen, $NHC(O)R^9$ or OR^8, wherein said aryl, heteroaryl or C_{2-6}alkynyl is optionally substituted with one to three R^7;

R^5 and R^6 are independently hydrogen or heterocyclyl, wherein said heterocyclyl is optionally substituted with two substituents independently selected from C_{1-6}alkyl;

or R^5 and R^6 together with the carbon to which they are attached, form a ring B, which is a 3-14 membered cycloalkyl or heterocyclyl monocyclic ring, or a 9-14 membered bicyclic cycloalkyl or heterocyclyl ring; and wherein ring B is optionally substituted by one or two substituents independently selected from oxo, halogen, C_{1-6}alkyl or OR^8; and ring B is optionally fused with an aryl or heteroaryl to form a bicyclic system;

R^7 is independently C_{1-6}alkyl, halogen, cyano, C_{0-6}alkylC_{3-6}cycloalkyl, C_{1-6}haloalkyl, OC_{1-6}alkyl or C_{2-6}alkynyl, wherein said C_{1-6}alkyl, C_{0-6}alkylC_{3-6}cycloalkyl, C_{1-6}haloalkyl, OC_{1-6}alkyl or C_{2-6}alkynyl is optionally substituted with 1-3 substituents independently selected from halogen, cyano, C_{1-6}alkyl, C_{1-6}haloalkyl, OC_{1-6}alkyl and OC_{1-6}haloalkyl;

R^8 is independently C_{1-6}alkyl, C_{2-6}alkynyl or C_{1-6}haloalkyl, wherein said C_{1-6}alkyl, C_{1-6}haloalkyl, aryl or heteroaryl is optionally substituted with a group selected from halogen, cyano or C_{1-6}alkyl; and

R^9 is heteroaryl, wherein said heteroaryl is optionally substituted with halogen, cyano, OR^8, C_{1-6}haloalkyl or C_{1-6}alkyl;

13. A compound according to claim 1, selected from the group consisting of:
- 6-(3,5-Dichlorophenyl)-5'-methylspiro[chroman-4,2'-imidazol]-4'-amine;
- 6-(5-Chloropyridin-3-yl)-5'-methylspiro[chroman-4,2'-imidazol]-4'-amine;
- 6-(3,5-Difluorophenyl)-5'-methylspiro[chroman-4,2'-imidazol]-4'-amine;
- 6-(3,5-dimethylphenyl)-5'-methylspiro[chroman-4,2'-imidazol]-4'-amine;
- 6-(2,5-dimethoxyphenyl)-5'-methylspiro[chroman-4,2'-imidazol]-4'-amine;
- 6-(2,3-difluorophenyl)-5'-methylspiro[chroman-4,2'-imidazol]-4'-amine;
- 6-(2,5-dimethylphenyl)-5'-methylspiro[chroman-4,2'-imidazol]-4'-amine;
- 6-(5-fluoro-2-methoxyphenyl)-5'-methylspiro[chroman-4,2'-imidazol]-4'-amine;
- 6-(2-fluoro-3-methoxyphenyl)-5'-methylspiro[chroman-4,2'-imidazol]-4'-amine;
- 6-(2-methoxy-5-methylphenyl)-5'-methylspiro[chroman-4,2'-imidazol]-4'-amine;
- 6-(2-fluoro-5-methylphenyl)-5'-methylspiro[chroman-4,2'-imidazol]-4'-amine;

- 6-(2-fluoro-5-methoxyphenyl)-5'-methylspiro[chroman-4,2'-imidazol]-4'-amine;
- N-(4'-amino-5'-methyl-spiro[chromane-4,2'-imidazole]-6-yl)-5-chloro-pyridine-2-carboxamide;
- N-(4'-amino-5'-methyl-spiro[chromane-4,2'-imidazole]-6-yl)-5-(trifluoromethyl)pyridine-2-carboxamide;
- N-(4'-amino-5'-methyl-spiro[chromane-4,2'-imidazole]-6-yl)-5-but-2-ynoxy-pyridine-2-carboxamide;
- N-(4'-amino-5'-methyl-spiro[chromane-4,2'-imidazole]-6-yl)-5-but-2-ynoxy-pyrazine-2-carboxamide;
- N-(4'-amino-5'-methyl-spiro[chromane-4,2'-imidazole]-6-yl)-5-methyl-thiophene-2-carboxamide;
- N-(4'-amino-5'-methyl-spiro[chromane-4,2'-imidazole]-6-yl)-3,5-dichloro-pyridine-2-carboxamide;
- 6'-bromo-4-(difluoromethoxy)-5"-methyl-3'*H*-dispiro[cyclohexane-1,2'-indene-1',2"-imidazol]-4"-amine;
- 6'-bromo-4-methoxy-5"-methyl-3'*H*-dispiro[cyclohexane-1,2'-indene-1',2"-imidazol]-4"-amine;
- 4-methoxy-5"-methyl-6'-[5-(prop-1-yn-1-yl)pyridin-3-yl]-3'H-dispiro[cyclohexane-1,2'-indene-1',2"-imidazol]-4"-amine;
- 4-methoxy-5"-methyl-6'-[4-(prop-1-yn-1-yl)pyridin-2-yl]-3'H-dispiro[cyclohexane-1,2'-indene-1',2"-imidazol]-4"-amine;
- 5-(4"-amino-4-methoxy-5"-methyl-3'H-dispiro[cyclohexane-1,2'-indene-1',2"-imidazol]-6'-yl)benzene-1,3-dicarbonitrile;
- 3-(4"-amino-4-methoxy-5"-methyl-3'H-dispiro[cyclohexane-1,2'-indene-1',2"-imidazol]-6'-yl)-5-chlorobenzonitrile;
- 6'-(5-chloropyridin-3-yl)-4-methoxy-5"-methyl-3'H-dispiro[cyclohexane-1,2'-indene-1',2"-imidazol]-4"-amine;
- 6'-(5-fluoropyridin-3-yl)-4-methoxy-5"-methyl-3'H-dispiro[cyclohexane-1,2'-indene-1',2"-imidazol]-4"-amine;
- 5-(4"-amino-4-methoxy-5"-methyl-3'H-dispiro[cyclohexane-1,2'-indene-1',2"-imidazol]-6'-yl)-2-fluorobenzonitrile;
- 6'-(3,3-dimethylbut-1-yn-1-yl)-4-methoxy-5"-methyl-3'H-dispiro[cyclohexane-1,2'-indene-1',2"-imidazol]-4"-amine;

- 6'-(cyclopropylethynyl)-4-methoxy-5"-methyl-3'H-dispiro[cyclohexane-1,2'-indene-1',2"-imidazol]-4"-amine;
- N-(4"-amino-4-methoxy-5"-methyl-3'H-dispiro[cyclohexane-1,2'-indene-1',2"-imidazol]-6'-yl)-5-bromopyrimidine-2-carboxamide;
- N-(4"-amino-4-methoxy-5"-methyl-3'H-dispiro[cyclohexane-1,2'-indene-1',2"-imidazol]-6'-yl)-5-(trifluoromethyl)pyridine-2-carboxamide;
- N-(4"-amino-4-methoxy-5"-methyl-3'H-dispiro[cyclohexane-1,2'-indene-1',2"-imidazol]-6'-yl)-5-chloro-3-methyl-1-benzofuran-2-carboxamide;
- N-(4"-amino-4-methoxy-5"-methyl-3'H-dispiro[cyclohexane-1,2'-indene-1',2"-imidazol]-6'-yl)-3,5-dichloropyridine-2-carboxamide;
- N-(4"-amino-4-methoxy-5"-methyl-3'H-dispiro[cyclohexane-1,2'-indene-1',2"-imidazol]-6'-yl)-5-chloropyridine-2-carboxamide;
- 4-methoxy-5"-methyl-6'-(2-methylpropoxy)-3'H-dispiro[cyclohexane-1,2'-indene-1',2"-imidazol]-4"-amine;
- 4-methoxy-5"-methyl-6'-(3,3,3-trifluoropropoxy)-3'H-dispiro[cyclohexane-1,2'-indene-1',2"-imidazol]-4"-amine;
- 6'-(3-fluoropropoxy)-4-methoxy-5"-methyl-3'H-dispiro[cyclohexane-1,2'-indene-1',2"-imidazol]-4"-amine;
- 6'-bromo-5-methyl-2",3",5",6"-tetrahydro-3'*H*-dispiro[imidazole-2,1'-indene-2',4"-pyran]-4-amine;
- 6'-(3-chlorophenyl)-5-methyl-2",3",5",6"-tetrahydro-3'H-dispiro[imidazole-2,1'-indene-2',4"-pyran]-4-amine;
- 6'-(3-chloro-4-fluorophenyl)-5-methyl-2",3",5",6"-tetrahydro-3'H-dispiro[imidazole-2,1'-indene-2',4"-pyran]-4-amine;
- 6'-bromo-4,4-difluoro-5"-methyl-3'*H*-dispiro[cyclohexane-1,2'-indene-1',2"-imidazol]-4"-amine;
- 6'-(5-chloropyridin-3-yl)-4,4-difluoro-5"-methyl-3'H-dispiro[cyclohexane-1,2'-indene-1',2"-imidazol]-4"-amine;
- N-(4"-amino-4,4-difluoro-5"-methyl-3'H-dispiro[cyclohexane-1,2'-indene-1',2"-imidazol]-6'-yl)-5-chloropyridine-2-carboxamide;
- 5'-bromo-4-methoxy-5"-methyldispiro[cyclohexane-1,2'-[1]benzofuran-3',2"-imidazol]-4"-amine;

- 5'-(3-chlorophenyl)-4-methoxy-5"-methyldispiro[cyclohexane-1,2'-[1]benzofuran-3',2"-imidazol]-4"-amine;
- 6'-bromo-5-methyl-5",6"-dihydro-4"*H*-dispiro[imidazole-2,4'-chromene-2',3"-pyran]-4-amine;
- 6'-(3-chlorophenyl)-5-methyl-5",6"-dihydro-4"H-dispiro[imidazole-2,4'-chromene-2',3"-pyran]-4-amine;
- 6'-(3-chloro-4-fluorophenyl)-5-methyl-5",6"-dihydro-4"H-dispiro[imidazole-2,4'-chromene-2',3"-pyran]-4-amine;
- 6-bromo-5'-methyl-2-tetrahydropyran-3-yl-spiro[chromane-4,2'-imidazole]-4'-amine;
- 6-(3-chlorophenyl)-5'-methyl-2-(tetrahydro-2H-pyran-3-yl)-2,3-dihydrospiro[chromene-4,2'-imidazol]-4'-amine;
- 6-bromo-2-(2,2-dimethyltetrahydropyran-4-yl)-5'-methyl-spiro[chromane-4,2'-imidazole]-4'-amine;
- 6-(3-chlorophenyl)-2-(2,2-dimethyltetrahydro-2H-pyran-4-yl)-5'-methyl-2,3-dihydrospiro[chromene-4,2'-imidazol]-4'-amine;
- N-(4"-amino-4-methoxy-5"-methyl-3'H-dispiro[cyclohexane-1,2'-indene-1',2"-imidazol]-6'-yl)-5-chloro-3-methylpyridine-2-carboxamide;
- N-(4"-amino-4-methoxy-5"-methyl-3'H-dispiro[cyclohexane-1,2'-indene-1',2"-imidazol]-6'-yl)-5-fluoropyridine-2-carboxamide;
- 4-methoxy-5"-methyl-6'-[2-(prop-1-yn-1-yl)pyridin-4-yl]-3'H-dispiro[cyclohexane-1,2'-indene-1',2"-imidazol]-4"-amine;
- 4-methoxy-5"-methyl-6'-[3-(prop-1-yn-1-yl)phenyl]-3'H-dispiro[cyclohexane-1,2'-indene-1',2"-imidazol]-4"-amine;
- 6'-(5-bromopyridin-3-yl)-4-methoxy-5"-methyl-3'*H*-dispiro[cyclohexane-1,2'-indene-1',2"-imidazol]-4"-amine;
- 4,4-difluoro-5"-methyl-6'-[5-(prop-1-yn-1-yl)pyridin-3-yl]-3'H-dispiro[cyclohexane-1,2'-indene-1',2"-imidazol]-4"-amine;
- 5'-(5-chloropyridin-3-yl)-4-methoxy-5"-methyldispiro[cyclohexane-1,2'-[1]benzofuran-3',2"-imidazol]-4"-amine;
- 4-methoxy-5"-methyl-5'-[5-(prop-1-yn-1-yl)pyridin-3-yl]dispiro[cyclohexane-1,2'-[1]benzofuran-3',2"-imidazol]-4"-amine;
- 7'-bromo-5-methyl-3',4'-dihydro-2'H-spiro[imidazole-2,1'-naphthalen]-4-amine;

- 7'-(5-chloropyridin-3-yl)-5-methyl-3',4'-dihydro-2'H-spiro[imidazole-2,1'-naphthalen]-4-amine;
- 5-methyl-7'-(5-(prop-1-ynyl)pyridin-3-yl)-3',4'-dihydro-2'H-spiro[imidazole-2,1'-naphthalen]-4-amine;
- 6'-bromo-5"-methyl-3'H-dispiro[cyclobutane-1, 2'-indene-1', 2"-imidazol]-4"-amine;
- 6'-(5-chloropyridin-3-yl)-5"-methyl-3'H-dispiro[cyclobutane-1,2'-indene-1',2"-imidazol]-4"-amine;
- 5"-methyl-6'-[5-(prop-1-yn-1-yl)pyridin-3-yl]-3'H-dispiro[cyclobutane-1,2'-indene-1',2"-imidazol]-4"-amine;
- 6'-(cyclopropylethynyl)-5"-methyl-3'H-dispiro[cyclobutane-1, 2'-indene-1', 2"-imidazol]-4"-amine;
- 6'-(3, 3-dimethylbut-1-yn-1-yl)-5"-methyl-3'H-dispiro[cyclobutane-1, 2'-indene-1', 2"-imidazol]-4"-amine;
- 6'-(5-chloro-6-methylpyridin-3-yl)-4-methoxy-5"-methyl-3'H-dispiro[cyclohexane-1,2'-indene-1',2"-imidazol]-4"-amine;
- 6'-(5-chloro-2-methylpyridin-3-yl)-4-methoxy-5"-methyl-3'*H*-dispiro[cyclohexane-1,2'-indene-1',2"-imidazol]-4"-amine;
- 4-methoxy-5"-methyl-6'-[4-methyl-5-(prop-1-yn-1-yl)pyridin-3-yl]-3'H-dispiro[cyclohexane-1,2'-indene-1',2"-imidazol]-4"-amine;
- 6'-bromo-5"-ethyl-4-methoxy-3'*H*-dispiro[cyclohexane-1,2'-indene-1',2"-imidazol]-4"-amine;
- 6'-(5-chloropyridin-3-yl)-5"-ethyl-4-methoxy-3'*H*-dispiro[cyclohexane-1,2'-indene-1',2"-imidazol]-4"-amine;
- 5"-ethyl-4-methoxy-6'-[5-(prop-1-yn-1-yl)pyridin-3-yl]-3'*H*-dispiro[cyclohexane-1,2'-indene-1',2"-imidazol]-4"-amine;
- 5-(4"-amino-5"-ethyl-4-methoxy-3'*H*-dispiro[cyclohexane-1,2'-indene-1',2"-imidazol]-6'-yl)pyridine-3-carbonitrile;
- 3-(4"-amino-5"-ethyl-4-methoxy-3'*H*-dispiro[cyclohexane-1,2'-indene-1',2"-imidazol]-6'-yl)benzonitrile;
- 6'-[5-(but-1-yn-1-yl)pyridin-3-yl]-4-methoxy-5"-methyl-3'*H*-dispiro[cyclohexane-1,2'-indene-1',2"-imidazol]-4"-amine;
- 4"-amino-5"-methyl-6'-[5-(prop-1-yn-1-yl)pyridin-3-yl]-3'*H*-dispiro[cyclohexane-1,2'-indene-1',2"-imidazol]-4-ol;

- 3-(4"-amino-4-methoxy-5"-methyl-3'*H*-dispiro[cyclohexane-1,2'-indene-1',2"-imidazol]-6'-yl)-5-methylbenzonitrile;
- 3-(4"-amino-4-methoxy-5"-methyl-3'*H*-dispiro[cyclohexane-1,2'-indene-1',2"-imidazol]-6'-yl)-5-fluorobenzonitrile;
- 6'-bromo-5"-methyl-3'H-dispiro[cyclopropane-1,2'-indene-1',2"-imidazol]-4"-amine;
- 3-(4"-amino-5"-methyl-3'H-dispiro[cyclopropane-1,2'-indene-1',2"-imidazol]-6'-yl)-5-chlorobenzonitrile;
- 4"-amino-4-methoxy-5"-methyl-3'H-dispiro[cyclohexane-1,2'-indene-1',2"-imidazole]-6'-carbonitrile;
- 4-methoxy-6'-[3-(methoxymethyl)phenyl]-5"-methyl-3'H-dispiro[cyclohexane-1,2'-indene-1',2"-imidazol]-4"-amine;
- 6'-[3-fluoro-5-(methoxymethyl)phenyl]-4-methoxy-5"-methyl-3'H-dispiro[cyclohexane-1,2'-indene-1',2"-imidazol]-4"-amine;
- 4-methoxy-5"-methyl-6'-{5-[(2,2,2-trifluoroethoxy)methyl]pyridin-3-yl}-3'H-dispiro[cyclohexane-1,2'-indene-1',2"-imidazol]-4"-amine;
- 4-methoxy-5"-methyl-6'-(5-methylpyridin-3-yl)-3'*H*-dispiro[cyclohexane-1,2'-indene-1',2"-imidazol]-4"-amine;
- 4-methoxy-5"-methyl-6'-[5-(trifluoromethyl)pyridin-3-yl]-3'*H*-dispiro[cyclohexane-1,2'-indene-1',2"-imidazol]-4"-amine;
- 3-(4"-amino-4-methoxy-5"-methyl-3'*H*-dispiro[cyclohexane-1,2'-indene-1',2"-imidazol]-6'-yl)-5-(trifluoromethyl)benzonitrile;
- 3-(4"-amino-4-methoxy-5"-methyl-3'*H*-dispiro[cyclohexane-1,2'-indene-1',2"-imidazol]-6'-yl)-5-(difluoromethyl)benzonitrile;
- 5-(4"-amino-4-methoxy-5"-methyl-3'H-dispiro[cyclohexane-1,2'-indene-1',2"-imidazol]-6'-yl)-2-fluoro-3-methoxybenzonitrile;
- 6'-(3,5-difluorophenyl)-4-methoxy-5"-methyl-3'*H*-dispiro[cyclohexane-1,2'-indene-1',2"-imidazol]-4"-amine;
- 6'-(2-fluoro-3-methoxyphenyl)-4-methoxy-5"-methyl-3'H-dispiro[cyclohexane-1,2'-indene-1',2"-imidazol]-4"-amine;
- 4-methoxy-5"-methyl-6'-phenyl-3'H-dispiro[cyclohexane-1,2'-indene-1',2"-imidazol]-4"-amine;
- 3-(4"-amino-4-methoxy-5"-methyl-3'*H*-dispiro[cyclohexane-1,2'-indene-1',2"-imidazol]-6'-yl)-5-methoxybenzonitrile;

- 3-(4"-amino-4-methoxy-5"-methyl-3'*H*-dispiro[cyclohexane-1,2'-indene-1',2"-imidazol]-6'-yl)-5-bromobenzonitrile;
- 3-(4"-amino-4-methoxy-5"-methyl-3'*H*-dispiro[cyclohexane-1,2'-indene-1',2"-imidazol]-6'-yl)-5-ethylbenzonitrile;
- 3-(4"-amino-4-methoxy-5"-methyl-3'*H*-dispiro[cyclohexane-1,2'-indene-1',2"-imidazol]-6'-yl)-5-(methoxymethyl)benzonitrile;
- 6'-(2-fluoro-5-methoxyphenyl)-4-methoxy-5"-methyl-3'H-dispiro[cyclohexane-1,2'-indene-1',2"-imidazol]-4"-amine;
- 6'-(2,5-difluorophenyl)-4-methoxy-5"-methyl-3'H-dispiro[cyclohexane-1,2'-indene-1',2"-imidazol]-4"-amine;
- 5-(4"-amino-4-methoxy-5"-methyl-3'H-dispiro[cyclohexane-1,2'-indene-1',2"-imidazol]-6'-yl)-3-chloro-2-fluorobenzonitrile;
- 6'-(2,3-difluorophenyl)-4-methoxy-5"-methyl-3'H-dispiro[cyclohexane-1,2'-indene-1',2"-imidazol]-4"-amine;
- 3-(4"-amino-4-methoxy-5"-methyl-3'H-dispiro[cyclohexane-1,2'-indene-1',2"-imidazol]-6'-yl)-4-fluorobenzonitrile;
- 6'-(2,4-difluorophenyl)-4-methoxy-5"-methyl-3'H-dispiro[cyclohexane-1,2'-indene-1',2"-imidazol]-4"-amine;
- 6'-(2,3-dichlorophenyl)-4-methoxy-5"-methyl-3'*H*-dispiro[cyclohexane-1,2'-indene-1',2"-imidazol]-4"-amine;
- 3-(4"-amino-4-(difluoromethoxy)-5"-methyl-3'H-dispiro[cyclohexane-1,2'-indene-1',2"-imidazol]-6'-yl)-5-fluorobenzonitrile;
- 3-(4"-amino-4-(difluoromethoxy)-5"-methyl-3'H-dispiro[cyclohexane-1,2'-indene-1',2"-imidazol]-6'-yl)-5-methoxybenzonitrile;
- 4-(difluoromethoxy)-5"-methyl-6'-[5-(trifluoromethyl)pyridin-3-yl]-3'H-dispiro[cyclohexane-1,2'-indene-1',2"-imidazol]-4"-amine;
- 3-(4"-amino-4-(difluoromethoxy)-5"-methyl-3'H-dispiro[cyclohexane-1,2'-indene-1',2"-imidazol]-6'-yl)-5-chlorobenzonitrile;
- 4-(difluoromethoxy)-6'-(3,5-difluorophenyl)-5"-methyl-3'H-dispiro[cyclohexane-1,2'-indene-1',2"-imidazol]-4"-amine;
- 5-(4"-amino-4-(difluoromethoxy)-5"-methyl-3'H-dispiro[cyclohexane-1,2'-indene-1',2"-imidazol]-6'-yl)-2-fluoro-3-methoxybenzonitrile;

- 4-methoxy-4,5"-dimethyl-6'-[5-(prop-1-yn-1-yl)pyridin-3-yl]-3'*H*-dispiro[cyclohexane-1,2'-indene-1',2"-imidazol]-4"-amine;
- 6'-(cyclobutylethynyl)-4-methoxy-5"-methyl-3'H-dispiro[cyclohexane-1,2'-indene-1',2"-imidazol]-4"-amine;
- 4-methoxy-5"-methyl-6'-(3-methylbut-1-yn-1-yl)-3'H-dispiro[cyclohexane-1,2'-indene-1',2"-imidazol]-4"-amine;
- 4-methoxy-5"-methyl-6'-{5-[($^2H_3$)prop-1-yn-1-yl]pyridin-3-yl}-3'*H*-dispiro[cyclohexane-1,2'-indene-1',2"-imidazol]-4"-amine;
- 3-(4"-amino-5"-methyl-4-oxodispiro[cyclohexane-1,2'-[1H]indene-1'(3'H),2"-[2H]imidazol]-6'-yl)-5-fluorobenzonitrile;
- 4-methoxy-5"-methyl-6'-(3-methyl-1H-pyrrolo[2,3-b]pyridin-5-yl)-3'H-dispiro[cyclohexane-1,2'-indene-1',2"-imidazol]-4"-amine;
- 6'-bromo-5"-methyl-4-[($^2H_3$)methyloxy]-3'H-dispiro[cyclohexane-1,2'-indene-1',2"-imidazol]-4"-amine;
- 3-(4"-amino-5"-methyl-4-[($^2H_3$)methyloxy]-3'H-dispiro[cyclohexane-1,2'-indene-1',2"-imidazol]-6'-yl)-5-fluorobenzonitrile;
- 6'-(5-chloropyridin-3-yl)-5"-methyl-4-[($^2H_3$)methyloxy]-3'H-dispiro[cyclohexane-1,2'-indene-1',2"-imidazol]-4"-amine;
- 6'-[5-(difluoromethyl)pyridin-3-yl]-4-methoxy-5"-methyl-3'*H*-dispiro[cyclohexane-1,2'-indene-1',2"-imidazol]-4"-amine;
- 4-methoxy-5"-methyl-6'-(3-methyl-1H-indol-5-yl)-3'H-dispiro[cyclohexane-1,2'-indene-1',2"-imidazol]-4"-amine;
- 5"-methyl-4-[($^2H_3$)methyloxy]-6'-[5-(prop-1-yn-1-yl)pyridin-3-yl]-3'*H*-dispiro[cyclohexane-1,2'-indene-1',2"-imidazol]-4"-amine;
- 6'-[2-chloro-3-(prop-1-yn-1-yl)phenyl]-4-methoxy-5"-methyl-3'H-dispiro[cyclohexane-1,2'-indene-1',2"-imidazol]-4"-amine;
- 6'-bromo-5"-methyl-4-(trifluoromethyl)-3'H-dispiro[cyclohexane-1,2'-indene-1',2"-imidazol]-4"-amine;
- 3-(4"-amino-5"-methyl-4-[($^2H_3$)methyloxy]-3'H-dispiro[cyclohexane-1,2'-indene-1',2"-imidazol]-6'-yl)-5-chlorobenzonitrile;
- 6'-(cyclobutylmethoxy)-4-methoxy-5"-methyl-3'H-dispiro[cyclohexane-1,2'-indene-1',2"-imidazol]-4"-amine;

- 5-(4"-amino-4-methoxy-5"-methyl-3'H-dispiro[cyclohexane-1,2'-indene-1',2"-imidazol]-6'-yl)-2-fluoro-3-(methoxymethyl)benzonitrile;
- 6'-bromo-4-(difluoromethyl)-5"-methyl-3'H-dispiro[cyclohexane-1,2'-indene-1',2"-imidazol]-4"-amine;
- 6'-(5-chloropyridin-3-yl)-4-(difluoromethyl)-5"-methyl-3'H-dispiro[cyclohexane-1,2'-indene-1',2"-imidazol]-4"-amine;
- 6'-bromo-4-ethoxy-5"-methyl-3'*H*-dispiro[cyclohexane-1,2'-indene-1',2"-imidazol]-4"-amine;
- 4-ethoxy-5"-methyl-6'-[5-(trifluoromethyl)pyridin-3-yl]-3'H-dispiro[cyclohexane-1,2'-indene-1',2"-imidazol]-4"-amine;
- 3-(4"-amino-4-ethoxy-5"-methyl-3'H-dispiro[cyclohexane-1,2'-indene-1',2"-imidazol]-6'-yl)-5-fluorobenzonitrile;
- 6'-(5-chloropyridin-3-yl)-4-ethoxy-5"-methyl-3'H-dispiro[cyclohexane-1,2'-indene-1',2"-imidazol]-4"-amine;
- 3-(4"-amino-4-ethoxy-5"-methyl-3'H-dispiro[cyclohexane-1,2'-indene-1',2"-imidazol]-6'-yl)-5-(difluoromethyl)benzonitrile; and
- 4-ethoxy-5"-methyl-6'-[5-(prop-1-yn-1-yl)pyridin-3-yl]-3'H-dispiro[cyclohexane-1,2'-indene-1',2"-imidazol]-4"-amine,

or a pharmaceutically acceptable salt of any foregoing compound.

14. A compound according to claim 1, which is (1r,1'R,4R)-4-methoxy-5"-methyl-6'-[5-(prop-1-yn-1-yl)pyridin-3-yl]-3'H-dispiro[cyclohexane-1,2'-indene-1',2"-imidazol]-4"-amine or a pharmaceutically acceptable salt thereof.

15. A compound according to claim 1, which is 3-[(1r,1'R,4R)-4"-amino-4-methoxy-5"-methyl-3'H-dispiro[cyclohexane-1,2'-indene-1',2"-imidazol]-6'-yl]-5-chlorobenzonitrile, or a pharmaceutically acceptable salt thereof.

16. A compound according to claim 1, which is (1r,4r)-4-methoxy-5"-methyl-6'-(2-methylpropoxy)-3'H-dispiro[cyclohexane-1,2'-indene-1',2"-imidazol]-4"-amine (isomer 1), or a pharmaceutically acceptable salt thereof.

17. A pharmaceutical composition comprising as active ingredient a therapeutically effective amount of a compound according to any one of claims 1 to 16, or a pharmaceutically acceptable salt thereof, in association with at least one pharmaceutically acceptable excipient, carrier or diluent.

18. A compound according to any one of claims 1 to 16, or a pharmaceutically acceptable salt thereof, for use as a medicament.

19. A compound according to any one of claims 1 to 16, or a pharmaceutically acceptable salt thereof, for treating or preventing an Aβ-related pathology.

20. A compound according to any one of claims 1 to 16, or a pharmaceutically acceptable salt thereof, for treating or preventing an Aβ-related pathology, wherein said Aβ-related pathology is Down's syndrome, a β-amyloid angiopathy, cerebral amyloid angiopathy, hereditary cerebral hemorrhage, a disorder associated with cognitive impairment, MCI ("mild cognitive impairment"), Alzheimer's Disease, memory loss, attention deficit symptoms associated with Alzheimer's disease, neurodegeneration associated with Alzheimer's Disease, dementia of mixed vascular origin, dementia of degenerative origin, pre-senile dementia, senile dementia, dementia associated with Parkinson's disease, progressive supranuclear palsy or cortical basal degeneration.

21. A compound according to any one of claims 1 to 16, or a pharmaceutically acceptable salt thereof, for treating or preventing Alzheimer's disease.

22. A compound according to any one of claims 1 to 16, or a pharmaceutically acceptable salt thereof, for use in the treatment or prevention of an Aβ-related pathology in a patient in need thereof.

23. Use of a compound according to any one of claims 1 to 16, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for the treatment or prevention of an Aβ-related pathology in a patient in need thereof.

24. The compound of claim 22, wherein said Aβ-related pathology is Down's syndrome, a β-amyloid angiopathy, cerebral amyloid angiopathy, hereditary cerebral hemorrhage, a

disorder associated with cognitive impairment, MCI ("mild cognitive impairment"), Alzheimer's Disease, memory loss, attention deficit symptoms associated with Alzheimer's disease, neurodegeneration associated with Alzheimer's disease, dementia of mixed vascular origin, dementia of degenerative origin, pre-senile dementia, senile dementia, dementia associated with Parkinson's disease, progressive supranuclear palsy or cortical basal degeneration.

25. The use of claim 23, wherein said Aβ-related pathology is Down's syndrome, a β-amyloid angiopathy, cerebral amyloid angiopathy, hereditary cerebral hemorrhage, a disorder associated with cognitive impairment, MCI ("mild cognitive impairment"), Alzheimer's Disease, memory loss, attention deficit symptoms associated with Alzheimer's disease, neurodegeneration associated with Alzheimer's disease, dementia of mixed vascular origin, dementia of degenerative origin, pre-senile dementia, senile dementia, dementia associated with Parkinson's disease, progressive supranuclear palsy or cortical basal degeneration.

26. A compound according to any one of claims 1 to 16, or a pharmaceutically acceptable salt thereof, for use in the treatment or prevention of Alzheimer's Disease in a patient in need thereof.

27. Use of a compound according to any one of claims 1 to 16, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for the treatment or prevention of Alzheimer's Disease in a patient in need thereof.

28. A compound according to any one of claims 1 to 16, or a pharmaceutically acceptable salt thereof, and at least one cognitive enhancing agent, memory enhancing agent, or choline esterase inhibitor, for use in the treatment or prevention of an Aβ-related pathology in a patient in need thereof.

29. Use of a compound according to any one of claims 1 to 16, or a pharmaceutically acceptable salt thereof, and at least one cognitive enhancing agent, memory enhancing agent, or choline esterase inhibitor , in the manufacture of a medicament for the treatment or prevention of an Aβ-related pathology in a patient in need thereof.

CLAIMS

1. A compound according to formula (I):



(I)

wherein

A is -O- or -CH_2-;

n is 0 or 1;

R^1 is C_{1-6}alkyl or C_{1-6}haloalkyl;

R^2 is hydrogen, C_{0-6}alkylaryl, C_{0-6}alkylheteroaryl, C_{2-6}alkynyl, C_{2-6}alkenyl, C_{1-6}alkyl, halogen, cyano, C_{1-6}haloalkyl, NHC(O)R^9 or OR^8, wherein said C_{0-6}alkylaryl, C_{0-6}alkylheteroaryl, C_{2-6}alkynyl, C_{2-6}alkenyl, C_{1-6}alkyl or C_{1-6}haloalkyl is optionally substituted with one to three R^7;

R^5 and R^6 are independently hydrogen, heterocyclyl, C_{3-6}cycloalkyl, aryl, heteroaryl or C_{1-6}alkyl, wherein said heterocyclyl, C_{3-6}cycloalkyl, aryl, heteroaryl or C_{1-6}alkyl is optionally substituted with one or two substituents independently selected from halogen, C_{1-6}alkyl, C_{1-6}haloalkyl, cyano or OR^8;
or R^5 and R^6 together with the carbon to which they are attached, form a ring B, which is a 3-14 membered cycloalkyl or heterocyclyl monocyclic ring, or a 9-14 membered bicyclic cycloalkyl or heterocyclyl ring; and wherein ring B is optionally substituted by one or two substituents

independently selected from oxo, halogen, C_{1-6}alkyl, C_{1-6}haloalkyl, cyano, or OR^8; and ring B is optionally fused with an aryl or heteroaryl to form a bi- or polycyclic system;

R^7 is independently C_{1-6}alkyl, halogen, cyano, C_{0-6}alkylC_{3-6}cycloalkyl, C_{1-6}haloalkyl, OC_{1-6}alkyl, OC_{1-6}haloalkyl, C_{2-6}alkynyl or C_{2-6}alkenyl, wherein said C_{1-6}alkyl, C_{0-6}alkylC_{3-6}cycloalkyl, C_{1-6}haloalkyl, OC_{1-6}alkyl, OC_{1-6}haloalkyl, C_{2-6}alkynyl or C_{2-6}alkenyl is optionally substituted with 1-3 substituents independently selected from halogen, cyano, C_{1-6}alkyl, C_{1-6}haloalkyl, OC_{1-6}alkyl and OC_{1-6}haloalkyl;

R^8 is independently hydrogen, C_{1-6}alkyl, C_{2-6}alkynyl, C_{1-6}haloalkyl, aryl or heteroaryl, wherein said C_{1-6}alkyl, C_{1-6}haloalkyl, aryl or heteroaryl is optionally substituted with a group selected from halogen, cyano and C_{1-6}alkyl;

R^9 is a heteroaryl, wherein said heteroaryl is optionally substituted with halogen, cyano, OR^8, C_{1-6}haloalkyl or C_{1-6}alkyl;

wherein said heteroaryl refers to a heteroaromatic heterocycle having 1 to 20 carbon atoms and one or more heteroatoms independently selected from sulfur, oxygen and nitrogen; and

wherein said heterocyclyl refers to a saturated, unsaturated or partially saturated, monocyclic, bicyclic or tricyclic ring containing 3 to 20 atoms of which 1, 2, 3, 4 or 5 ring atoms are independently chosen from nitrogen, sulphur and oxygen;

as a free base or a pharmaceutically acceptable salt thereof.

2. A compound according to claim 1, or a pharmaceutically acceptable salt thereof, wherein R^1 is C_{1-3}alkyl.

3. A compound according to claim 2, or a pharmaceutically acceptable salt thereof, wherein R^1 is methyl or ethyl.

4. A compound according to any one of claims 1-3, or a pharmaceutically acceptable salt thereof, wherein R^2 is aryl, heteroaryl, C_{2-6}alkynyl, halogen, $NHC(O)R^9$ or OR^8, wherein said aryl, heteroaryl, or C_{2-6}alkynyl is optionally substituted with one to three R^7.

5. A compound according to any one of claims 1-4, or a pharmaceutically acceptable salt thereof, wherein R^5 and R^6 are independently hydrogen or heterocyclyl wherein said heterocyclyl is optionally substituted with one or two substituents independently selected from C_{1-6}alkyl or OR^8.

6. A compound according to any one of claims 1-4, or a pharmaceutically acceptable salt thereof, wherein R^5 and R^6 together with the carbon to which they are attached, form a ring B, which is a 3-14 membered cycloalkyl or heterocyclyl monocyclic ring, or a 9-14 membered bicyclic cycloalkyl or heterocyclyl ring; and wherein ring B is optionally substituted by one or two substituents independently selected from oxo, halogen, C_{1-6}alkyl or OR^8; and ring B is optionally fused with an aryl or heteroaryl to form a bi- or polycyclic system.

7. A compound according to any one of claims 1-4 or 6, or a pharmaceutically acceptable salt thereof, wherein R^5 and R^6 together with the carbon to which they are attached form a cyclohexyl ring, which is substituted with OR^8.

8. A compound according to any one of claims 1-7, or a pharmaceutically acceptable salt thereof, wherein R^7 is independently C_{1-6}alkyl, halogen, cyano, C_{0-6}alkylC_{3-6}cycloalkyl, C_{1-6}haloalkyl, OC_{1-6}alkyl or C_{2-6}alkynyl, wherein said C_{1-6}alkyl, C_{0-6}alkylC_{3-6}cycloalkyl, C_{1-6}haloalkyl, OC_{1-6}alkyl or C_{2-6}alkynyl is optionally substituted with 1-3 substituents independently selected from halogen, cyano, C_{1-6}alkyl, C_{1-6}haloalkyl, OC_{1-6}alkyl and OC_{1-6}haloalkyl.

9. A compound according to any one of claims 1-8, or a pharmaceutically acceptable salt thereof, wherein R^8 is independently C_{1-6}alkyl, C_{2-6}alkynyl or C_{1-6}haloalkyl.

10. A compound according to any one of claims 1-9, or a pharmaceutically acceptable salt thereof, wherein R^9 is heteroaryl, wherein said heteroaryl is optionally substituted with halogen, cyano, OR^8, C_{1-6}haloalkyl or C_{1-6}alkyl.

11. A compound according to claim 1, or a pharmaceutically acceptable salt thereof, wherein

A is -O- or $-CH_2-$;
n is 0 or 1;

R^1 is C_{1-6}alkyl;

R^2 is C_{0-6}alkylaryl, C_{0-6}alkylheteroaryl, C_{2-6}alkynyl, halogen, $NHC(O)R^9$ or OR^8; wherein said C_{0-6}alkylaryl, C_{0-6}alkylheteroaryl or C_{2-6}alkynyl is optionally substituted with one to three R^7;

R^5 and R^6 are independently hydrogen or heterocyclyl, wherein said heterocyclyl is optionally substituted with one or two substituents independently selected from halogen, C_{1-6}alkyl, C_{1-6}haloalkyl, cyano or OR^8;
or R^5 and R^6 together with the carbon to which they are attached, form a ring B, which is a 3-14 membered cycloalkyl or heterocyclyl monocyclic ring, or a 9-14 membered bicyclic cycloalkyl or heterocyclyl ring; and wherein ring B is optionally substituted by one or two substituents independently selected from oxo, halogen, C_{1-6}alkyl or OR^8; and ring B is optionally fused with an aryl or heteroaryl to form a bi- or polycyclic system;

R^7 is independently C_{1-6}alkyl, halogen, cyano, C_{0-6}alkylC_{3-6}cycloalkyl, C_{1-6}haloalkyl, OC_{1-6}alkyl or C_{2-6}alkynyl, wherein said C_{1-6}alkyl, C_{0-6}alkylC_{3-6}cycloalkyl, C_{1-6}haloalkyl, OC_{1-6}alkyl or C_{2-6}alkynyl, is optionally substituted with 1-3 substituents independently selected from halogen, cyano, C_{1-6}alkyl, C_{1-6}haloalkyl, OC_{1-6}alkyl and OC_{1-6}haloalkyl;

R^8 is independently C_{1-6}alkyl, C_{2-6}alkynyl or C_{1-6}haloalkyl, wherein said C_{1-6}alkyl, C_{1-6}haloalkyl, aryl or heteroaryl is optionally substituted with a group selected from halogen, cyano or C_{1-6}alkyl; and

R^9 is heteroaryl, wherein said heteroaryl is optionally substituted with halogen, cyano, OR^8, C_{1-6}haloalkyl or C_{1-6}alkyl;

12. A compound according to claim 1, or a pharmaceutically acceptable salt thereof, wherein

A is -O- or -CH_2 -;
n is 0 or 1;

R^1 is C_{1-3}alkyl;

R^2 is aryl, heteroaryl, C_{2-6}alkynyl, halogen, $NHC(O)R^9$ or OR^8, wherein said aryl, heteroaryl or C_{2-6}alkynyl is optionally substituted with one to three R^7;

R^5 and R^6 are independently hydrogen or heterocyclyl, wherein said heterocyclyl is optionally substituted with two substituents independently selected from C_{1-6}alkyl;

or R^5 and R^6 together with the carbon to which they are attached, form a ring B, which is a 3-14 membered cycloalkyl or heterocyclyl monocyclic ring, or a 9-14 membered bicyclic cycloalkyl or heterocyclyl ring; and wherein ring B is optionally substituted by one or two substituents independently selected from oxo, halogen, C_{1-6}alkyl or OR^8; and ring B is optionally fused with an aryl or heteroaryl to form a bicyclic system;

R^7 is independently C_{1-6}alkyl, halogen, cyano, C_{0-6}alkylC_{3-6}cycloalkyl, C_{1-6}haloalkyl, OC_{1-6}alkyl or C_{2-6}alkynyl, wherein said C_{1-6}alkyl, C_{0-6}alkylC_{3-6}cycloalkyl, C_{1-6}haloalkyl, OC_{1-6}alkyl or C_{2-6}alkynyl is optionally substituted with 1-3 substituents independently selected from halogen, cyano, C_{1-6}alkyl, C_{1-6}haloalkyl, OC_{1-6}alkyl and OC_{1-6}haloalkyl;

R^8 is independently C_{1-6}alkyl, C_{2-6}alkynyl or C_{1-6}haloalkyl, wherein said C_{1-6}alkyl, C_{1-6}haloalkyl, aryl or heteroaryl is optionally substituted with a group selected from halogen, cyano or C_{1-6}alkyl; and

R^9 is heteroaryl, wherein said heteroaryl is optionally substituted with halogen, cyano, OR^8, C_{1-6}haloalkyl or C_{1-6}alkyl;

13. A compound according to claim 1, selected from the group consisting of:

- 6-(3,5-Dichlorophenyl)-5'-methylspiro[chroman-4,2'-imidazol]-4'-amine;
- 6-(5-Chloropyridin-3-yl)-5'-methylspiro[chroman-4,2'-imidazol]-4'-amine;
- 6-(3,5-Difluorophenyl)-5'-methylspiro[chroman-4,2'-imidazol]-4'-amine;
- 6-(3,5-dimethylphenyl)-5'-methylspiro[chroman-4,2'-imidazol]-4'-amine;
- 6-(2,5-dimethoxyphenyl)-5'-methylspiro[chroman-4,2'-imidazol]-4'-amine;
- 6-(2,3-difluorophenyl)-5'-methylspiro[chroman-4,2'-imidazol]-4'-amine;
- 6-(2,5-dimethylphenyl)-5'-methylspiro[chroman-4,2'-imidazol]-4'-amine;
- 6-(5-fluoro-2-methoxyphenyl)-5'-methylspiro[chroman-4,2'-imidazol]-4'-amine;
- 6-(2-fluoro-3-methoxyphenyl)-5'-methylspiro[chroman-4,2'-imidazol]-4'-amine;
- 6-(2-methoxy-5-methylphenyl)-5'-methylspiro[chroman-4,2'-imidazol]-4'-amine;
- 6-(2-fluoro-5-methylphenyl)-5'-methylspiro[chroman-4,2'-imidazol]-4'-amine;
- 6-(2-fluoro-5-methoxyphenyl)-5'-methylspiro[chroman-4,2'-imidazol]-4'-amine;
- N-(4'-amino-5'-methyl-spiro[chromane-4,2'-imidazole]-6-yl)-5-chloro-pyridine-2-carboxamide;
- N-(4'-amino-5'-methyl-spiro[chromane-4,2'-imidazole]-6-yl)-5-(trifluoromethyl)pyridine-2-carboxamide;
- N-(4'-amino-5'-methyl-spiro[chromane-4,2'-imidazole]-6-yl)-5-but-2-ynoxy-pyridine-2-carboxamide;
- N-(4'-amino-5'-methyl-spiro[chromane-4,2'-imidazole]-6-yl)-5-but-2-ynoxy-pyrazine-2-carboxamide;

- N-(4'-amino-5'-methyl-spiro[chromane-4,2'-imidazole]-6-yl)-5-methyl-thiophene-2-carboxamide;
- N-(4'-amino-5'-methyl-spiro[chromane-4,2'-imidazole]-6-yl)-3,5-dichloro-pyridine-2-carboxamide;
- 6'-bromo-4-(difluoromethoxy)-5"-methyl-3'*H*-dispiro[cyclohexane-1,2'-indene-1',2"-imidazol]-4"-amine;
- 6'-bromo-4-methoxy-5"-methyl-3'*H*-dispiro[cyclohexane-1,2'-indene-1',2"-imidazol]-4"-amine;
- 4-methoxy-5"-methyl-6'-[5-(prop-1-yn-1-yl)pyridin-3-yl]-3'H-dispiro[cyclohexane-1,2'-indene-1',2"-imidazol]-4"-amine;
- 4-methoxy-5"-methyl-6'-[4-(prop-1-yn-1-yl)pyridin-2-yl]-3'H-dispiro[cyclohexane-1,2'-indene-1',2"-imidazol]-4"-amine;
- 5-(4"-amino-4-methoxy-5"-methyl-3'H-dispiro[cyclohexane-1,2'-indene-1',2"-imidazol]-6'-yl)benzene-1,3-dicarbonitrile;
- 3-(4"-amino-4-methoxy-5"-methyl-3'H-dispiro[cyclohexane-1,2'-indene-1',2"-imidazol]-6'-yl)-5-chlorobenzonitrile;
- 6'-(5-chloropyridin-3-yl)-4-methoxy-5"-methyl-3'H-dispiro[cyclohexane-1,2'-indene-1',2"-imidazol]-4"-amine;
- 6'-(5-fluoropyridin-3-yl)-4-methoxy-5"-methyl-3'H-dispiro[cyclohexane-1,2'-indene-1',2"-imidazol]-4"-amine;
- 5-(4"-amino-4-methoxy-5"-methyl-3'H-dispiro[cyclohexane-1,2'-indene-1',2"-imidazol]-6'-yl)-2-fluorobenzonitrile;
- 6'-(3,3-dimethylbut-1-yn-1-yl)-4-methoxy-5"-methyl-3'H-dispiro[cyclohexane-1,2'-indene-1',2"-imidazol]-4"-amine;
- 6'-(cyclopropylethynyl)-4-methoxy-5"-methyl-3'H-dispiro[cyclohexane-1,2'-indene-1',2"-imidazol]-4"-amine;
- N-(4"-amino-4-methoxy-5"-methyl-3'H-dispiro[cyclohexane-1,2'-indene-1',2"-imidazol]-6'-yl)-5-bromopyrimidine-2-carboxamide;
- N-(4"-amino-4-methoxy-5"-methyl-3'H-dispiro[cyclohexane-1,2'-indene-1',2"-imidazol]-6'-yl)-5-(trifluoromethyl)pyridine-2-carboxamide;

- N-(4"-amino-4-methoxy-5"-methyl-3'H-dispiro[cyclohexane-1,2'-indene-1',2"-imidazol]-6'-yl)-5-chloro-3-methyl-1-benzofuran-2-carboxamide;
- N-(4"-amino-4-methoxy-5"-methyl-3'H-dispiro[cyclohexane-1,2'-indene-1',2"-imidazol]-6'-yl)-3,5-dichloropyridine-2-carboxamide;
- N-(4"-amino-4-methoxy-5"-methyl-3'H-dispiro[cyclohexane-1,2'-indene-1',2"-imidazol]-6'-yl)-5-chloropyridine-2-carboxamide;
- 4-methoxy-5"-methyl-6'-(2-methylpropoxy)-3'H-dispiro[cyclohexane-1,2'-indene-1',2"-imidazol]-4"-amine;
- 4-methoxy-5"-methyl-6'-(3,3,3-trifluoropropoxy)-3'H-dispiro[cyclohexane-1,2'-indene-1',2"-imidazol]-4"-amine;
- 6'-(3-fluoropropoxy)-4-methoxy-5"-methyl-3'H-dispiro[cyclohexane-1,2'-indene-1',2"-imidazol]-4"-amine;
- 6'-bromo-5-methyl-2",3",5",6"-tetrahydro-3'*H*-dispiro[imidazole-2,1'-indene-2',4"-pyran]-4-amine;
- 6'-(3-chlorophenyl)-5-methyl-2",3",5",6"-tetrahydro-3'H-dispiro[imidazole-2,1'-indene-2',4"-pyran]-4-amine;
- 6'-(3-chloro-4-fluorophenyl)-5-methyl-2",3",5",6"-tetrahydro-3'H-dispiro[imidazole-2,1'-indene-2',4"-pyran]-4-amine;
- 6'-bromo-4,4-difluoro-5"-methyl-3'*H*-dispiro[cyclohexane-1,2'-indene-1',2"-imidazol]-4"-amine;
- 6'-(5-chloropyridin-3-yl)-4,4-difluoro-5"-methyl-3'H-dispiro[cyclohexane-1,2'-indene-1',2"-imidazol]-4"-amine;
- N-(4"-amino-4,4-difluoro-5"-methyl-3'H-dispiro[cyclohexane-1,2'-indene-1',2"-imidazol]-6'-yl)-5-chloropyridine-2-carboxamide;
- 5'-bromo-4-methoxy-5"-methyldispiro[cyclohexane-1,2'-[1]benzofuran-3',2"-imidazol]-4"-amine;
- 5'-(3-chlorophenyl)-4-methoxy-5"-methyldispiro[cyclohexane-1,2'-[1]benzofuran-3',2"-imidazol]-4"-amine;
- 6'-bromo-5-methyl-5",6"-dihydro-4"*H*-dispiro[imidazole-2,4'-chromene-2',3"-pyran]-4-amine;

- 6'-(3-chlorophenyl)-5-methyl-5",6"-dihydro-4"H-dispiro[imidazole-2,4'-chromene-2',3"-pyran]-4-amine;
- 6'-(3-chloro-4-fluorophenyl)-5-methyl-5",6"-dihydro-4"H-dispiro[imidazole-2,4'-chromene-2',3"-pyran]-4-amine;
- 6-bromo-5'-methyl-2-tetrahydropyran-3-yl-spiro[chromane-4,2'-imidazole]-4'-amine;
- 6-(3-chlorophenyl)-5'-methyl-2-(tetrahydro-2H-pyran-3-yl)-2,3-dihydrospiro[chromene-4,2'-imidazol]-4'-amine;
- 6-bromo-2-(2,2-dimethyltetrahydropyran-4-yl)-5'-methyl-spiro[chromane-4,2'-imidazole]-4'-amine;
- 6-(3-chlorophenyl)-2-(2,2-dimethyltetrahydro-2H-pyran-4-yl)-5'-methyl-2,3-dihydrospiro[chromene-4,2'-imidazol]-4'-amine;
- N-(4"-amino-4-methoxy-5"-methyl-3'H-dispiro[cyclohexane-1,2'-indene-1',2"-imidazol]-6'-yl)-5-chloro-3-methylpyridine-2-carboxamide;
- N-(4"-amino-4-methoxy-5"-methyl-3'H-dispiro[cyclohexane-1,2'-indene-1',2"-imidazol]-6'-yl)-5-fluoropyridine-2-carboxamide;
- 4-methoxy-5"-methyl-6'-[2-(prop-1-yn-1-yl)pyridin-4-yl]-3'H-dispiro[cyclohexane-1,2'-indene-1',2"-imidazol]-4"-amine;
- 4-methoxy-5"-methyl-6'-[3-(prop-1-yn-1-yl)phenyl]-3'H-dispiro[cyclohexane-1,2'-indene-1',2"-imidazol]-4"-amine;
- 6'-(5-bromopyridin-3-yl)-4-methoxy-5"-methyl-3'*H*-dispiro[cyclohexane-1,2'-indene-1',2"-imidazol]-4"-amine;
- 4,4-difluoro-5"-methyl-6'-[5-(prop-1-yn-1-yl)pyridin-3-yl]-3'H-dispiro[cyclohexane-1,2'-indene-1',2"-imidazol]-4"-amine;
- 5'-(5-chloropyridin-3-yl)-4-methoxy-5"-methyldispiro[cyclohexane-1,2'-[1]benzofuran-3',2"-imidazol]-4"-amine;
- 4-methoxy-5"-methyl-5'-[5-(prop-1-yn-1-yl)pyridin-3-yl]dispiro[cyclohexane-1,2'-[1]benzofuran-3',2"-imidazol]-4"-amine;
- 7'-bromo-5-methyl-3',4'-dihydro-2'H-spiro[imidazole-2,1'-naphthalen]-4-amine;
- 7'-(5-chloropyridin-3-yl)-5-methyl-3',4'-dihydro-2'H-spiro[imidazole-2,1'-naphthalen]-4-amine;

- 5-methyl-7'-(5-(prop-1-ynyl)pyridin-3-yl)-3',4'-dihydro-2'H-spiro[imidazole-2,1'-naphthalen]-4-amine;
- 6'-bromo-5"-methyl-3'H-dispiro[cyclobutane-1, 2'-indene-1', 2"-imidazol]-4"-amine;
- 6'-(5-chloropyridin-3-yl)-5"-methyl-3'H-dispiro[cyclobutane-1,2'-indene-1',2"-imidazol]-4"-amine;
- 5"-methyl-6'-[5-(prop-1-yn-1-yl)pyridin-3-yl]-3'H-dispiro[cyclobutane-1,2'-indene-1',2"-imidazol]-4"-amine;
- 6'-(cyclopropylethynyl)-5"-methyl-3'H-dispiro[cyclobutane-1, 2'-indene-1', 2"-imidazol]-4"-amine;
- 6'-(3, 3-dimethylbut-1-yn-1-yl)-5"-methyl-3'H-dispiro[cyclobutane-1, 2'-indene-1', 2"-imidazol]-4"-amine;
- 6'-(5-chloro-6-methylpyridin-3-yl)-4-methoxy-5"-methyl-3'H-dispiro[cyclohexane-1,2'-indene-1',2"-imidazol]-4"-amine;
- 6'-(5-chloro-2-methylpyridin-3-yl)-4-methoxy-5"-methyl-3'*H*-dispiro[cyclohexane-1,2'-indene-1',2"-imidazol]-4"-amine;
- 4-methoxy-5"-methyl-6'-[4-methyl-5-(prop-1-yn-1-yl)pyridin-3-yl]-3'H-dispiro[cyclohexane-1,2'-indene-1',2"-imidazol]-4"-amine;
- 6'-bromo-5"-ethyl-4-methoxy-3'*H*-dispiro[cyclohexane-1,2'-indene-1',2"-imidazol]-4"-amine;
- 6'-(5-chloropyridin-3-yl)-5"-ethyl-4-methoxy-3'*H*-dispiro[cyclohexane-1,2'-indene-1',2"-imidazol]-4"-amine;
- 5"-ethyl-4-methoxy-6'-[5-(prop-1-yn-1-yl)pyridin-3-yl]-3'*H*-dispiro[cyclohexane-1,2'-indene-1',2"-imidazol]-4"-amine;
- 5-(4"-amino-5"-ethyl-4-methoxy-3'*H*-dispiro[cyclohexane-1,2'-indene-1',2"-imidazol]-6'-yl)pyridine-3-carbonitrile;
- 3-(4"-amino-5"-ethyl-4-methoxy-3'*H*-dispiro[cyclohexane-1,2'-indene-1',2"-imidazol]-6'-yl)benzonitrile;
- 6'-[5-(but-1-yn-1-yl)pyridin-3-yl]-4-methoxy-5"-methyl-3'*H*-dispiro[cyclohexane-1,2'-indene-1',2"-imidazol]-4"-amine;

- 4"-amino-5"-methyl-6'-[5-(prop-1-yn-1-yl)pyridin-3-yl]-3'*H*-dispiro[cyclohexane-1,2'-indene-1',2"-imidazol]-4-ol;
- 3-(4"-amino-4-methoxy-5"-methyl-3'*H*-dispiro[cyclohexane-1,2'-indene-1',2"-imidazol]-6'-yl)-5-methylbenzonitrile;
- 3-(4"-amino-4-methoxy-5"-methyl-3'*H*-dispiro[cyclohexane-1,2'-indene-1',2"-imidazol]-6'-yl)-5-fluorobenzonitrile;
- 6'-bromo-5"-methyl-3'H-dispiro[cyclopropane-1,2'-indene-1',2"-imidazol]-4"-amine;
- 3-(4"-amino-5"-methyl-3'H-dispiro[cyclopropane-1,2'-indene-1',2"-imidazol]-6'-yl)-5-chlorobenzonitrile;
- 4"-amino-4-methoxy-5"-methyl-3'H-dispiro[cyclohexane-1,2'-indene-1',2"-imidazole]-6'-carbonitrile;
- 4-methoxy-6'-[3-(methoxymethyl)phenyl]-5"-methyl-3'H-dispiro[cyclohexane-1,2'-indene-1',2"-imidazol]-4"-amine;
- 6'-[3-fluoro-5-(methoxymethyl)phenyl]-4-methoxy-5"-methyl-3'H-dispiro[cyclohexane-1,2'-indene-1',2"-imidazol]-4"-amine;
- 4-methoxy-5"-methyl-6'-{5-[(2,2,2-trifluoroethoxy)methyl]pyridin-3-yl}-3'H-dispiro[cyclohexane-1,2'-indene-1',2"-imidazol]-4"-amine;
- 4-methoxy-5"-methyl-6'-(5-methylpyridin-3-yl)-3'*H*-dispiro[cyclohexane-1,2'-indene-1',2"-imidazol]-4"-amine;
- 4-methoxy-5"-methyl-6'-[5-(trifluoromethyl)pyridin-3-yl]-3'*H*-dispiro[cyclohexane-1,2'-indene-1',2"-imidazol]-4"-amine;
- 3-(4"-amino-4-methoxy-5"-methyl-3'*H*-dispiro[cyclohexane-1,2'-indene-1',2"-imidazol]-6'-yl)-5-(trifluoromethyl)benzonitrile;
- 3-(4"-amino-4-methoxy-5"-methyl-3'*H*-dispiro[cyclohexane-1,2'-indene-1',2"-imidazol]-6'-yl)-5-(difluoromethyl)benzonitrile;
- 5-(4"-amino-4-methoxy-5"-methyl-3'H-dispiro[cyclohexane-1,2'-indene-1',2"-imidazol]-6'-yl)-2-fluoro-3-methoxybenzonitrile;
- 6'-(3,5-difluorophenyl)-4-methoxy-5"-methyl-3'*H*-dispiro[cyclohexane-1,2'-indene-1',2"-imidazol]-4"-amine;
- 6'-(2-fluoro-3-methoxyphenyl)-4-methoxy-5"-methyl-3'H-dispiro[cyclohexane-1,2'-indene-

1',2"-imidazol]-4"-amine;

- 4-methoxy-5"-methyl-6'-phenyl-3'H-dispiro[cyclohexane-1,2'-indene-1',2"-imidazol]-4"-amine;
- 3-(4"-amino-4-methoxy-5"-methyl-3'*H*-dispiro[cyclohexane-1,2'-indene-1',2"-imidazol]-6'-yl)-5-methoxybenzonitrile;
- 3-(4"-amino-4-methoxy-5"-methyl-3'*H*-dispiro[cyclohexane-1,2'-indene-1',2"-imidazol]-6'-yl)-5-bromobenzonitrile;
- 3-(4"-amino-4-methoxy-5"-methyl-3'*H*-dispiro[cyclohexane-1,2'-indene-1',2"-imidazol]-6'-yl)-5-ethylbenzonitrile;
- 3-(4"-amino-4-methoxy-5"-methyl-3'*H*-dispiro[cyclohexane-1,2'-indene-1',2"-imidazol]-6'-yl)-5-(methoxymethyl)benzonitrile;
- 6'-(2-fluoro-5-methoxyphenyl)-4-methoxy-5"-methyl-3'H-dispiro[cyclohexane-1,2'-indene-1',2"-imidazol]-4"-amine;
- 6'-(2,5-difluorophenyl)-4-methoxy-5"-methyl-3'H-dispiro[cyclohexane-1,2'-indene-1',2"-imidazol]-4"-amine;
- 5-(4"-amino-4-methoxy-5"-methyl-3'H-dispiro[cyclohexane-1,2'-indene-1',2"-imidazol]-6'-yl)-3-chloro-2-fluorobenzonitrile;
- 6'-(2,3-difluorophenyl)-4-methoxy-5"-methyl-3'H-dispiro[cyclohexane-1,2'-indene-1',2"-imidazol]-4"-amine;
- 3-(4"-amino-4-methoxy-5"-methyl-3'H-dispiro[cyclohexane-1,2'-indene-1',2"-imidazol]-6'-yl)-4-fluorobenzonitrile;
- 6'-(2,4-difluorophenyl)-4-methoxy-5"-methyl-3'H-dispiro[cyclohexane-1,2'-indene-1',2"-imidazol]-4"-amine;
- 6'-(2,3-dichlorophenyl)-4-methoxy-5"-methyl-3'*H*-dispiro[cyclohexane-1,2'-indene-1',2"-imidazol]-4"-amine;
- 3-(4"-amino-4-(difluoromethoxy)-5"-methyl-3'H-dispiro[cyclohexane-1,2'-indene-1',2"-imidazol]-6'-yl)-5-fluorobenzonitrile;
- 3-(4"-amino-4-(difluoromethoxy)-5"-methyl-3'H-dispiro[cyclohexane-1,2'-indene-1',2"-imidazol]-6'-yl)-5-methoxybenzonitrile;
- 4-(difluoromethoxy)-5"-methyl-6'-[5-(trifluoromethyl)pyridin-3-yl]-3'H-

dispiro[cyclohexane-1,2'-indene-1',2"-imidazol]-4"-amine;

- 3-(4"-amino-4-(difluoromethoxy)-5"-methyl-3'H-dispiro[cyclohexane-1,2'-indene-1',2"-imidazol]-6'-yl)-5-chlorobenzonitrile;
- 4-(difluoromethoxy)-6'-(3,5-difluorophenyl)-5"-methyl-3'H-dispiro[cyclohexane-1,2'-indene-1',2"-imidazol]-4"-amine;
- 5-(4"-amino-4-(difluoromethoxy)-5"-methyl-3'H-dispiro[cyclohexane-1,2'-indene-1',2"-imidazol]-6'-yl)-2-fluoro-3-methoxybenzonitrile;
- 4-methoxy-4,5"-dimethyl-6'-[5-(prop-1-yn-1-yl)pyridin-3-yl]-3'*H*-dispiro[cyclohexane-1,2'-indene-1',2"-imidazol]-4"-amine;
- 6'-(cyclobutylethynyl)-4-methoxy-5"-methyl-3'H-dispiro[cyclohexane-1,2'-indene-1',2"-imidazol]-4"-amine;
- 4-methoxy-5"-methyl-6'-(3-methylbut-1-yn-1-yl)-3'H-dispiro[cyclohexane-1,2'-indene-1',2"-imidazol]-4"-amine;
- 4-methoxy-5"-methyl-6'-{5-[($^2H_3$)prop-1-yn-1-yl]pyridin-3-yl}-3'*H*-dispiro[cyclohexane-1,2'-indene-1',2"-imidazol]-4"-amine;
- 3-(4"-amino-5"-methyl-4-oxodispiro[cyclohexane-1,2'-[1H]indene-1'(3'H),2"-[2H]imidazol]-6'-yl)-5-fluorobenzonitrile;
- 4-methoxy-5"-methyl-6'-(3-methyl-1H-pyrrolo[2,3-b]pyridin-5-yl)-3'H-dispiro[cyclohexane-1,2'-indene-1',2"-imidazol]-4"-amine;
- 6'-bromo-5"-methyl-4-[($^2H_3$)methyloxy]-3'H-dispiro[cyclohexane-1,2'-indene-1',2"-imidazol]-4"-amine;
- 3-(4"-amino-5"-methyl-4-[($^2H_3$)methyloxy]-3'H-dispiro[cyclohexane-1,2'-indene-1',2"-imidazol]-6'-yl)-5-fluorobenzonitrile;
- 6'-(5-chloropyridin-3-yl)-5"-methyl-4-[($^2H_3$)methyloxy]-3'H-dispiro[cyclohexane-1,2'-indene-1',2"-imidazol]-4"-amine;
- 6'-[5-(difluoromethyl)pyridin-3-yl]-4-methoxy-5"-methyl-3'*H*-dispiro[cyclohexane-1,2'-indene-1',2"-imidazol]-4"-amine;
- 4-methoxy-5"-methyl-6'-(3-methyl-1H-indol-5-yl)-3'H-dispiro[cyclohexane-1,2'-indene-1',2"-imidazol]-4"-amine;

- 5"-methyl-4-[($^2H_3$)methyloxy]-6'-[5-(prop-1-yn-1-yl)pyridin-3-yl]-3'*H*-dispiro[cyclohexane-1,2'-indene-1',2"-imidazol]-4"-amine;
- 6'-[2-chloro-3-(prop-1-yn-1-yl)phenyl]-4-methoxy-5"-methyl-3'H-dispiro[cyclohexane-1,2'-indene-1',2"-imidazol]-4"-amine;
- 6'-bromo-5"-methyl-4-(trifluoromethyl)-3'H-dispiro[cyclohexane-1,2'-indene-1',2"-imidazol]-4"-amine;
- 3-(4"-amino-5"-methyl-4-[($^2H_3$)methyloxy]-3'H-dispiro[cyclohexane-1,2'-indene-1',2"-imidazol]-6'-yl)-5-chlorobenzonitrile;
- 6'-(cyclobutylmethoxy)-4-methoxy-5"-methyl-3'H-dispiro[cyclohexane-1,2'-indene-1',2"-imidazol]-4"-amine;
- 5-(4"-amino-4-methoxy-5"-methyl-3'H-dispiro[cyclohexane-1,2'-indene-1',2"-imidazol]-6'-yl)-2-fluoro-3-(methoxymethyl)benzonitrile;
- 6'-bromo-4-(difluoromethyl)-5"-methyl-3'H-dispiro[cyclohexane-1,2'-indene-1',2"-imidazol]-4"-amine;
- 6'-(5-chloropyridin-3-yl)-4-(difluoromethyl)-5"-methyl-3'H-dispiro[cyclohexane-1,2'-indene-1',2"-imidazol]-4"-amine;
- 6'-bromo-4-ethoxy-5"-methyl-3'*H*-dispiro[cyclohexane-1,2'-indene-1',2"-imidazol]-4"-amine;
- 4-ethoxy-5"-methyl-6'-[5-(trifluoromethyl)pyridin-3-yl]-3'H-dispiro[cyclohexane-1,2'-indene-1',2"-imidazol]-4"-amine;
- 3-(4"-amino-4-ethoxy-5"-methyl-3'H-dispiro[cyclohexane-1,2'-indene-1',2"-imidazol]-6'-yl)-5-fluorobenzonitrile;
- 6'-(5-chloropyridin-3-yl)-4-ethoxy-5"-methyl-3'H-dispiro[cyclohexane-1,2'-indene-1',2"-imidazol]-4"-amine;
- 3-(4"-amino-4-ethoxy-5"-methyl-3'*H*-dispiro[cyclohexane-1,2'-indene-1',2"-imidazol]-6'-yl)-5-(difluoromethyl)benzonitrile; and
- 4-ethoxy-5"-methyl-6'-[5-(prop-1-yn-1-yl)pyridin-3-yl]-3'H-dispiro[cyclohexane-1,2'-indene-1',2"-imidazol]-4"-amine,

or a pharmaceutically acceptable salt of any foregoing compound.

14. A compound according to claim 1, which is (1r,1'R,4R)-4-methoxy-5"-methyl-6'-[5-(prop-1-yn-1-yl)pyridin-3-yl]-3'H-dispiro[cyclohexane-1,2'-indene-1',2"-imidazol]-4"-amine:



,

or a pharmaceutically acceptable salt thereof.

15. A compound according to claim 1, which is 3-[(1r,1'R,4R)-4"-amino-4-methoxy-5"-methyl-3'H-dispiro[cyclohexane-1,2'-indene-1',2"-imidazol]-6'-yl]-5-chlorobenzonitrile:



,

or a pharmaceutically acceptable salt thereof.

16. A compound according to claim 1, which is (1r,4r)-4-methoxy-5"-methyl-6'-(2-methyl-propoxy)-3'H-dispiro[cyclohexane-1,2'-indene-1',2"-imidazol]-4"-amine (isomer 1):



(isomer 1),

or a pharmaceutically acceptable salt thereof.

17. A pharmaceutical composition comprising as active ingredient a therapeutically effective amount of a compound according to any one of claims 1 to 16, or a pharmaceutically acceptable salt thereof, in association with at least one pharmaceutically acceptable excipient, carrier or diluent.

18. A compound according to any one of claims 1 to 16, or a pharmaceutically acceptable salt thereof, for use as a medicament.

19. A compound according to any one of claims 1 to 16, or a pharmaceutically acceptable salt thereof, for treating or preventing an Aβ-related pathology.

20. A compound according to any one of claims 1 to 16, or a pharmaceutically acceptable salt thereof, for treating or preventing an Aβ-related pathology, wherein said Aβ-related pathology is Down's syndrome, a β-amyloid angiopathy, cerebral amyloid angiopathy, hereditary cerebral hemorrhage, a disorder associated with cognitive impairment, MCI ("mild cognitive impairment"), Alzheimer's Disease, memory loss, attention deficit symptoms associated with Alzheimer's disease, neurodegeneration associated with Alzheimer's Disease, dementia of mixed vascular origin, dementia of degenerative origin, pre-senile dementia, senile dementia, dementia associated with Parkinson's disease, progressive supranuclear palsy or cortical basal degeneration.

21. A compound according to any one of claims 1 to 16, or a pharmaceutically acceptable salt thereof, for treating or preventing Alzheimer's disease.

22. A compound according to any one of claims 1 to 16, or a pharmaceutically acceptable salt thereof, for use in the treatment or prevention of an Aβ-related pathology in a patient in need thereof.

23. The use of a compound according to any one of claims 1 to 16, or a pharmaceutically acceptable salt thereof, for the manufacture of a medicament for the treatment or prevention of an Aβ-related pathology.

24. The compound of claim 22, wherein said Aβ-related pathology is Down's syndrome, a β-amyloid angiopathy, cerebral amyloid angiopathy, hereditary cerebral hemorrhage, a disorder associated with cognitive impairment, MCI ("mild cognitive impairment"), Alzheimer's

Disease, memory loss, attention deficit symptoms associated with Alzheimer's disease, neurodegeneration associated with Alzheimer's disease, dementia of mixed vascular origin, dementia of degenerative origin, pre-senile dementia, senile dementia, dementia associated with Parkinson's disease, progressive supranuclear palsy or cortical basal degeneration.

25. The use of claim 23, wherein said Aβ-related pathology is Down's syndrome, a β-amyloid angiopathy, cerebral amyloid angiopathy, hereditary cerebral hemorrhage, a disorder associated with cognitive impairment, MCI ("mild cognitive impairment"), Alzheimer's Disease, memory loss, attention deficit symptoms associated with Alzheimer's disease, neurodegeneration associated with Alzheimer's disease, dementia of mixed vascular origin, dementia of degenerative origin, pre-senile dementia, senile dementia, dementia associated with Parkinson's disease, progressive supranuclear palsy or cortical basal degeneration.

26. A compound according to any one of claims 1 to 16, or a pharmaceutically acceptable salt thereof, for use in the treatment or prevention of Alzheimer's Disease in a patient in need thereof.

27. Use of a compound according to any one of claims 1 to 16, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for the treatment or prevention of Alzheimer's Disease in a patient in need thereof.

28. A compound according to any one of claims 1 to 16, or a pharmaceutically acceptable salt thereof, and at least one cognitive enhancing agent, memory enhancing agent, or choline esterase inhibitor, for use in the treatment or prevention of an Aβ-related pathology in a patient in need thereof.

29. Use of a compound according to any one of claims 1 to 16, or a pharmaceutically acceptable salt thereof, and at least one cognitive enhancing agent, memory enhancing agent, or choline esterase inhibitor , in the manufacture of a medicament for the treatment or prevention of an Aβ-related pathology in a patient in need thereof.